MedTrace Logo

Comparison of Sirolimus Alone With Sirolimus Plus Tacrolimus in Type 1 Diabetic Recipients of Cultured Islet Cell Grafts

NCT00409461 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL

Last updated 2006-12-11

No results posted yet for this study

Summary

Proof of concept study in islet transplantation, two treatment arms (ATG SIR-TAC versus ATG SIR) each consisting of ten type 1 diabetic patients

Conditions

Interventions

DRUG

ATG-Sirolimus-Tacrolimus

Sponsors & Collaborators

  • Fund for Scientific Research, Flanders, Belgium

    collaborator OTHER

  • Belgian Government

    collaborator OTHER_GOV

  • AZ-VUB

    lead OTHER

Principal Investigators

  • Bart Keymeulen, MD, PhD · AZ-VUB

Study Design

Allocation
NON_RANDOMIZED
Masking
NONE
Model
FACTORIAL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • Belgium

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00409461 on ClinicalTrials.gov